Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.55 |
| ▸ | PPARA | Q07869 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14188875 | 0.93 | MEN1 (0.60) | MEN1KMT2ATP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL487084 | 0.88 | POLB (0.59) | MEN1KMT2AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL2098794 | 0.86 | ALDH1A1 (0.74) | MEN1KMT2ATP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL30817424 | 0.86 | ALDH1A1 (0.74) | MEN1KMT2ATP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL9312746 | 0.80 | KMT2A (1.00) | MEN1KMT2ATP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL10640761 | 0.80 | HPGD (0.71) | MEN1KMT2ATP53ALDH1A1HPGD | |
| SCHEMBL13010627 | 0.80 | KMT2A (0.72) | MEN1KMT2ATP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL6360691 | 0.79 | KMT2A (0.77) | MEN1KMT2ATP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL13437936 | 0.79 | KMT2A (0.82) | MEN1KMT2ATP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL2902945 | 0.77 | KMT2A (0.79) | MEN1KMT2ATP53ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137621-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | DIASOME PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20250288521-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | DIASOME PHARMACEUTICALS INC (US) | 2025-09-18 | — | — | US | claimed |
| CN-104666246-A | Orally Bioavailable Lipid-based Constructs | SDG INC AN OHIO CORPRATION | 2015-06-03 | — | — | CN | claimed |
| US-20110135725-A1 | Lipid Construct for Delivery of Insulin to a Mammal | SDG, INC. (US) | 2011-06-09 | — | — | US | claimed |
| WO-2011022396-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG, INC. (US) | 2011-02-24 | — | — | WO | claimed |
| US-7871641-B2 | Hepatocyte-targeting vehicle for delivery of glargine insulin to a mammal | SDG, INC. (US) | 2011-01-18 | — | — | US | claimed |
| US-7858116-B2 | Hepatocyte delivery vehicle for delivery of a combination of recombinant human regular insulin and recombinant human insulin isophane to a mammal | SDG, INC. (US) | 2010-12-28 | — | — | US | claimed |
| CN-101917971-A | Orally bioavailable lipid-based structures | SDG INC AN OHIO CORP | 2010-12-15 | — | — | CN | claimed |
| EP-2205217-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG, INC. (an Ohio Corporation ) (US) | 2010-07-14 | — | — | EP | claimed |
| WO-2009042945-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG, INC. (AN OHIO CORPORATION ) (US) | 2009-04-02 | — | — | WO | claimed |
| US-20090087479-A1 | Orally bioavailable lipid-based constructs | SDG, INC. ( AN OHIO CORPORATION) (US) | 2009-04-02 | — | — | US | claimed |
| EP-1883394-A2 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG, Inc. (US) | 2008-02-06 | — | — | EP | claimed |
| WO-2006127361-A2 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG, INC. (US) | 2006-11-30 | — | — | WO | claimed |
| US-20060222698-A1 | Hepatocyte delivery vehicle for delivery of glargine insulin to a mammal | SDG, INC. | 2006-10-05 | — | — | US | claimed |
| US-20060222697-A1 | Hepatocyte delivery vehicle for delivery of a combination of recombinant human regular insulin and recombinant human insulin isophane to a mammal | SDG, INC. | 2006-10-05 | — | — | US | claimed |
| US-20260137621-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | DIASOME PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260124139-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | DIASOME PHARMACEUTICALS INC (US) | 2026-05-07 | — | — | US | disclosed |
| WO-1999059545-A9 | TARGETED LIPOSOMAL DRUG DELIVERY SYSTEM | SDG INC (US) | 2000-04-27 | — | — | WO | disclosed |
| WO-1999059545-A1 | TARGETED LIPOSOMAL DRUG DELIVERY SYSTEM | SDG, INC. (US) | 1999-11-25 | — | — | WO | disclosed |
| EP-0274467-B1 | HEPATOCYTE DIRECTED VESICLE DELIVERY SYSTEM | GEHO, W., Blair (US) | 1992-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250288521-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, FABP6 | MEN1 966/4885KMT2A 4850/4885TP53 800/4885 |
| US-20260137621-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, SGMS2 | MEN1 2415/4885KMT2A 4861/4885TP53 1896/4885 |
| US-20260124139-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | GPR119, INSR, FABP1 | MEN1 2073/4885KMT2A 4687/4885TP53 4117/4885 |
| US-20060222698-A1 | Hepatocyte delivery vehicle for delivery of glargine insulin to a mammal | INSR, GPR119, GCG | MEN1 1834/4885KMT2A 2791/4885TP53 962/4885 |
| US-20090087479-A1 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | MEN1 1343/4885KMT2A 4779/4885TP53 728/4885 |
| US-20110135725-A1 | Lipid Construct for Delivery of Insulin to a Mammal | INSR, IAPP, GPR119 | MEN1 1400/4885KMT2A 4621/4885TP53 3236/4885 |
| US-20060222697-A1 | Hepatocyte delivery vehicle for delivery of a combination of recombinant human regular insulin and recombinant human insulin isophane to a mammal | INSR, INSRR, IAPP | MEN1 1710/4885KMT2A 3700/4885TP53 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.